SRI31277

SRI31277 is a **synthetic tripeptide inhibitor** (sequence: serine-lysine-leucine) developed to block thrombospondin-1 (TSP-1)-mediated activation of latent transforming growth factor-beta (TGF-β). By selectively blocking the interaction between TSP-1 and latent TGF-β, SRI31277 inhibits activation of TGF-β signaling pathways. This mechanism targets a source of TGF-β activation implicated in drug resistance in cancers such as multiple myeloma and thyroid carcinoma, as well as fibrosis. SRI31277 has been found to be effective in preclinical models for both cancer drug resistance (e.g., overcoming bortezomib resistance in multiple myeloma) and fibrosis, though it has a short plasma half-life and is generally administered via infusion in animal studies. It was originated as a lead compound from research aiming to develop TSP-1/TGF-β antagonists, with analogs under further development for improved stability and bioavailability[1][3][5][7].

Other names

SRI-31277SRI31277SRI 31277